References in periodicals archive ?
The maximum range in the healthy tissue for tositumomab is only 2.
Another novel yet effective treatment is radio immunotherapy (RIT) which allows delivery of radiation to lymphoma cells using radioimmunoconjugates ([131]I- tositumomab and [90]Y-ibritutomomab tiuxetan have been approved till now) that target the CD20 antigen and are being used in the setting of recurrent follicular lymphoma setting.
The antineoplastic agents are alemtuzumab (Campath), bevacizumab (Avastin), cetuximab (Erbitux), gemtuzumab ozogamicin (Mylotarg), ibritumomab tiuxetan (Zevalin), panitumumab (Vectibix), tositumomab and iodine 131 (Bexxar), and trastuzumab (Herceptin).
Marketed antibody drugs and advanced candidates are often directed to the same target and there are apparently four TNF[alpha] antagonists (infliximab, adalimumab, golimumab, certolizumab) in addition to the Fc fusion protein etanercept, five antibodies targeting the B cell receptor CD20 (rituximab, ibritumomab, tositumomab, ofatumumab, ocrelizumab), five to the EGF receptor EGFR (cetuximab, panitumumab, matuzumab, nimotuzumab, zalatumumab), and three to VEGF / VEGFR signalling (bevacizumab, ranibizumab, CDP-791) in addition to the Fc fusion VEGF-Trap.
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911.
In one study, the combined use of radioimmunotherapy with the anti-CD20 monoclonal antibody tositumomab and autologous hematopoietic stem cell transplantation was shown to be beneficial in adults aged 60 and over with high-risk relapsed or refractory B-cell lymphoma, Dr.
Radioimmunotherapy consisting of radiolabeled antibodies (such as tositumomab and ibritumomab) targeted to CD20 antigens on cancer cells in patients with relapsed or refractory FL has yielded overall response rates of about 80%, said Dr.
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab
G3001, Administration and supply of tositumomab, 450mg, for the infusion of non-radioactive tositumomab during the dosimetric step and the infusion of non-radioactive tositumomab during the therapeutic step.
Under a separate agreement, Boehringer Ingelheim Pharma KG produces bulk tositumomab, which is sent to MDS Nordion for radiolabeling.
Iodine 131 has a well-established safety profile in the treatment of thyroid disease and tositumomab has anti-tumor activity of its own.